• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Akebia Therapeutics Inc.

    4/30/25 10:57:38 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKBA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Akebia Therapeutics Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    00972D105

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    00972D105


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    136,460.00
    7Sole Dispositive Power

    12,470,283.00
    8Shared Dispositive Power

    215,520.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    12,685,803.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.37 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Akebia Therapeutics Inc
    (b)Address of issuer's principal executive offices:

    245 First Street, Suite 1100, Cambridge, MA, 02142
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    00972D105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    12685803
    (b)Percent of class:

    5.37  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    136460

     (iii) Sole power to dispose or to direct the disposition of:

    12470283

     (iv) Shared power to dispose or to direct the disposition of:

    215520

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:04/30/2025
    Get the next $AKBA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKBA

    DatePrice TargetRatingAnalyst
    6/4/2025$8.00Buy
    H.C. Wainwright
    4/28/2025$7.00Outperform
    Leerink Partners
    4/1/2025$6.00Buy
    Jefferies
    11/29/2023$4.00Buy
    BTIG Research
    8/28/2023$3.75Neutral → Buy
    H.C. Wainwright
    5/31/2023$2.00 → $4.00Neutral → Overweight
    Piper Sandler
    3/31/2022$10.00 → $2.00Buy → Neutral
    H.C. Wainwright
    3/31/2022Buy → Hold
    Needham
    More analyst ratings

    $AKBA
    SEC Filings

    View All

    SEC Form S-8 filed by Akebia Therapeutics Inc.

    S-8 - Akebia Therapeutics, Inc. (0001517022) (Filer)

    8/7/25 8:42:49 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Akebia Therapeutics Inc.

    10-Q - Akebia Therapeutics, Inc. (0001517022) (Filer)

    8/7/25 7:38:41 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)

    8/7/25 7:06:34 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

    Continued Vafseo® (vadadustat) growth with Q2 2025 net product revenues increasing to $13.3 million; Total Q2 2025 net product revenues increased to $60.5 million DaVita physicians are expected to begin treating patients with Vafseo in August 2025 as part of an operational pilot at 100+ DaVita dialysis clinics Patient enrollment completed in VOICE, a collaborative clinical trial of Vafseo conducted by USRC Akebia to host Conference Call at 8:00 a.m. ET on Thursday, August 7, 2025 CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, tod

    8/7/25 7:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics to Present at Canaccord Genuity's 45th Annual Growth Conference

    CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, will participate in a Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference on Wednesday, August 13 at 1:30 PM EDT. The conference will take place August 12-14, 2025 in Boston. A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com following the conference. About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmace

    8/6/25 8:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization

    CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a post-marketing study to identify additional potential benefits of Vafseo® (vadadustat). The VOCAL trial, conducted within DaVita clinics, aims to generate data to evaluate the efficacy and safety of three times per week (TIW) dosing of vadadustat compared to standard of care erythropoiesis-stimulating agents (ESA) in patients with anemia of CKD receiving in-center hemodialysis. "Our team and partners within the dialysis community share a commitment to improvin

    8/4/25 8:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VAFSEO issued to AKEBIA THERAPEUTICS INC

    Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity

    3/28/24 10:46:38 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Akebia Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $8.00

    6/4/25 7:33:29 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Akebia Therapeutics with a new price target

    Leerink Partners initiated coverage of Akebia Therapeutics with a rating of Outperform and set a new price target of $7.00

    4/28/25 8:36:09 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Akebia Therapeutics with a new price target

    Jefferies initiated coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $6.00

    4/1/25 9:03:14 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, CFO, CBO & Treasurer Ostrowski Erik sold $151,622 worth of shares (41,314 units at $3.67), decreasing direct ownership by 8% to 503,586 units (SEC Form 4)

    4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

    7/1/25 5:01:37 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Zumwalt Leanne M was granted 35,700 shares, increasing direct ownership by 48% to 109,400 units (SEC Form 4)

    4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

    6/11/25 5:16:36 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Adams Adrian was granted 35,700 shares, increasing direct ownership by 22% to 200,500 units (SEC Form 4)

    4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

    6/11/25 5:16:12 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    Leadership Updates

    Live Leadership Updates

    View All

    Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer

    CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Nicholas Grund as Chief Commercial Officer. Mr. Grund is a seasoned pharmaceutical executive with significant operational, commercial and strategic leadership experience across renal and specialty markets. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeut

    1/9/24 8:30:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics Appoints Ron Frieson, Healthcare Operations Leader, to Board of Directors

    CAMBRIDGE, Mass., Nov. 1, 2021 /PRNewswire/ -- Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Ron Frieson to its Board of Directors. Frieson currently serves as the Chief Operating Officer of Children's Healthcare of Atlanta (CHOA), a non-profit corporation whose mission focuses on bettering all aspects of children's healthcare. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt

    11/1/21 8:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    Financials

    Live finance-specific insights

    View All

    Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

    Continued Vafseo® (vadadustat) growth with Q2 2025 net product revenues increasing to $13.3 million; Total Q2 2025 net product revenues increased to $60.5 million DaVita physicians are expected to begin treating patients with Vafseo in August 2025 as part of an operational pilot at 100+ DaVita dialysis clinics Patient enrollment completed in VOICE, a collaborative clinical trial of Vafseo conducted by USRC Akebia to host Conference Call at 8:00 a.m. ET on Thursday, August 7, 2025 CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, tod

    8/7/25 7:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights

    CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, August 7, 2025, at 8:00 a.m. EDT to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time. A live webcast of the confere

    7/31/25 8:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

    CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, May 8, 2025, at 8:00 a.m. EDT to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.  A live webcast of the conference ca

    5/1/25 8:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

    SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

    2/13/24 4:58:48 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

    SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

    2/9/24 4:00:47 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

    SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

    2/10/23 1:08:17 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care